endothelin-3

Recombinant proteinexperimental

Endothelins are peptides with receptors and effects in many body organs. Endothelin constricts blood vessels and raises blood pressure. The endothelins are normally kept in balance by other mechanisms, but when overexpressed, they contribute to high blood pressure (hypertension), heart disease, and potentially other diseases. — Wikipedia

Clinical trial activity

4 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2008 (NCT00406731)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • endothelin-1
  • endothelin-1
  • endothelin-1
  • endothelin 1 (human)
  • endothelin 1 (human)
  • endothelin 1 (pig)
  • endothelin 1 (rat)
  • endothelin-3
  • endothelin (porcine)
  • human endothelin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02906085N/AOct 1, 2016University of Copenhagen
NCT01100736Early Phase 1 (Phase 1)Jan 1, 2009Encysive, University of Edinburgh
NCT00745693N/AMar 1, 2008Umea University, University of Edinburgh
NCT00406731Phase 2Jan 1, 2008University of Vienna
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of EdinburghAcademic/Hospital2222008
EncysiveFor profit1012009
Umea UniversityAcademic/Hospital1012008
University of CopenhagenAcademic/Hospital1112016
University of ViennaAcademic/Hospital1112008
5 organizations
Page 1 / 1